Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Gene Therapy to Target CD19 for Acute Lymphocytic Leukemia and Follicular lymphoma by Shenzhen BinDeBio for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval
Gene Therapy to Target CD19 for Acute Lymphocytic Leukemia and Follicular lymphoma is under clinical development by Shenzhen BinDeBio and...
Gene Therapy to Target CD19 for Acute Lymphocytic Leukemia and Follicular lymphoma by Shenzhen BinDeBio for Follicular Lymphoma: Likelihood of Approval
Gene Therapy to Target CD19 for Acute Lymphocytic Leukemia and Follicular lymphoma is under clinical development by Shenzhen BinDeBio and...
Gene Therapy to Target CD19 and CD22 for B-cell Acute Lymphoblastic Leukemia and Lymphoma by Shenzhen BinDeBio for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval
Gene Therapy to Target CD19 and CD22 for B-cell Acute Lymphoblastic Leukemia and Lymphoma is under clinical development by Shenzhen...
Gene Therapy to Target CD19 and CD22 for B-cell Acute Lymphoblastic Leukemia and Lymphoma by Shenzhen BinDeBio for Lymphoma: Likelihood of Approval
Gene Therapy to Target CD19 and CD22 for B-cell Acute Lymphoblastic Leukemia and Lymphoma is under clinical development by Shenzhen...